BioSyent Announces Changes to Executive Management
September 10 2018 - 5:28PM
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) today
announced changes to its Executive Management team:
Effective on September 10, 2018, Mr. Alfred
D’Souza has retired as Vice President, Finance and Chief Financial
Officer of the Company. “We greatly appreciate Mr. D’Souza’s
12 years of service to BioSyent and its shareholders and we thank
him for his significant contribution to the Company’s strategic
direction and growth during his tenure,” commented René Goehrum,
Chairman, President and CEO of BioSyent. Beyond today’s date,
Mr. D’Souza will ensure a smooth transition to his successor and
will continue to act in an advisory capacity to the Company on an
ongoing basis.
Effective with Mr. D’Souza’s retirement, Mr.
Robert March has joined BioSyent as Vice President, Finance and
Chief Financial Officer. Mr. March is a Chartered
Professional Accountant (CPA, CA), a Certified Public Accountant
(CPA, Illinois), and holds a MBA from St. Mary’s University and a
B.Sc. in Biochemistry, Microbiology and Immunology from Dalhousie
University. Robert started his career at Ernst & Young in
Audit and Assurance Services before being promoted to Manager in
Transaction Advisory Services, where his experience included
insolvency and restructuring as well as general transaction
services such as mergers and acquisitions. Prior to joining
BioSyent, Robert accumulated over 15 years of progressive
senior management experience in highly regulated industries in both
Canada and the USA, most recently serving as Chief Financial
Officer (and Co-Chief Operating Officer) for Ippolito Group of
Companies, a fresh and branded packaged foods supplier and
distribution services provider with customers across North
America.
“I am delighted to welcome Robert March to
BioSyent’s Executive Management team,” remarked René Goehrum.
“His skills and experiences are well-suited for the Company’s
strategic objectives and his values are well-aligned with those of
BioSyent. With the team developed by Mr. D’Souza, I am
confident that Mr. March can continue to build on the Company’s
successes to date and support the achievement of its future growth
objectives.”
Mr. Joost van der Mark has also joined
BioSyent’s Executive Management team as Vice President, Corporate
Development and will be responsible for business development and
market access initiatives. Mr. van der Mark is a seasoned
healthcare executive with over 20 years of experience in the
biopharmaceutical industry. Prior to joining BioSyent,
Mr. van der Mark was the Chief Business Officer for 3D Signatures
and previously, he co-founded Orphan Canada, which subsequently
sold its assets to Knight Therapeutics in 2014. Mr. van der
Mark has held progressive positions in clinical research, sales,
marketing, market access, strategy and business development at
Bayer, Sanofi, Nycomend (n.k.a. Takeda) and Knight
Therapeutics. He has a M.Sc. in Physiology/Pharmacology from
Western University and a MBA from York University (Schulich).
“I am pleased to welcome Joost van der Mark to
BioSyent,” noted René Goehrum. “He brings extensive industry
experience and knowledge to the Company and will be instrumental in
our efforts to continue to expand our product portfolio.”
The Company also wishes to announce that its
Board of Directors has passed a resolution to grant a total of
11,313 stock options to certain employees of BioSyent. These
option grants are made under the Company’s Incentive Stock Option
Plan (“the Plan”) approved by shareholders on May 29, 2018.
Each option entitles the optionee to purchase one common share of
the Company at an exercise price of $9.60. These options are
exercisable for a period of ten years from the date of grant.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the
trading symbol “RX”, BioSyent is a profitable growth-oriented
specialty pharmaceutical company focused on in-licensing or
acquiring innovative pharmaceutical and other healthcare products
that have been successfully developed, are safe and effective, and
have a proven track record of improving the lives of
patients. BioSyent supports the healthcare professionals that
treat these patients by marketing its products through its
community, hospital and international business units.
As of the date of this press release, the
Company has 14,519,603 common shares issued and outstanding.
For a direct market quote for the TSX Venture
Exchange and other Company financial information, please visit
www.tmxmoney.com.
For further information please
contact:
Mr. René C. GoehrumPresident and CEOBioSyent
Inc.Tel: (905) 206-0013E-Mail: investors@biosyent.comWeb:
www.biosyent.com
This press release may contain information or
statements that are forward-looking. The contents herein represent
our judgment, as at the release date, and are subject to risks and
uncertainties that may cause actual results or outcomes to be
materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to,
those associated with clinical trials, product development, future
revenue, operations, profitability and obtaining regulatory
approvals.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this press release.
Biosyent (TSXV:RX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Apr 2023 to Apr 2024